Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxyurea for EBV-Associated PCNSL in AIDS
NCT00002940Phase 2Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Oct 1996
- Primary completion
- Mar 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxyurea in primary central nervous system lymphoma (PCNSL), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Objective Response Rate at 56 days. Started Oct 1996; status: completed.
02
Drugs
hydroxyurea
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT00002940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002940.